JAK2 V617F Mutation Analysis - Qualitative

Code

MOG-JVQX-01BX

Test

Active-Compendium

81270

Clinical

Oncology,Pathology

Bone Marrow Aspirate: 2 mL in EDTA tube. 
Peripheral Blood: 5 mL in EDTA tube. 
Note: Test is RNA-based. Please select Extract & Hold - RNA If specimen hold service is desired.

Hematologic Diseases

Myeloproliferative neoplasm (MPN)

Wed, 04/30/2025 - 12:00

Fri, 08/01/2025 - 12:00

Molecular

Global

Flag Active

True

Orderable Test Description

This test uses PCR for qualitative detection of the JAK2 V617F and V617I mutations. Testing is performed on plasma for increased sensitivity whenever possible.
 
Test Customization: JAK2617F testing may be ordered concurrently with JAK2 exon 12-13 sequencing, or with reflex to exon 12-13 sequencing.

Orderable Turn Around Time

7 Days

Keywords

Meta Description

Detects the V617F mutation. The rare mutation V617I is also detected. Testing is performed on plasma for increased sensitivity whenever possible.

Orderable Biomarkers

JAK2

NY Approved

True

Orderable Biomarkers JSON

{"DNA Sequencing": {"SNVs + Indels": ["JAK2"]}}

Keywords string

jak2, jak 2, v617f, jak JAK2 V617F Mutation Analysis - Qualitative

Title URL

jak2-v617f-mutation-analysis-qualitative

Clinical Significance

The JAK2 V617F mutation is present in approximately 90% of polycythemia vera (PV) cases and approximately 40% of primary myelofibrosis (PMF) or essential thrombocythemia (ET). Mutation analysis helps differentiate reactive conditions from myeloproliferative neoplasms (MPNs).

Storage and transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible. NYS clients please provide date and time of collection. Please select Extract & Hold - RNA if specimen hold service is desired.